🇺🇸 FDA

Company profile · Sponsor

Adaptive

Adaptive Biotechnologies Corp

ADPT · NYSE biotech SEATTLE, WA, USA
Pipeline
19
Drugs
0
Patents
8

Quick answer

Adaptive (ADPT) is a biotech company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 19 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ADPT
Exchange NYSE
Company type biotech
Headquarters SEATTLE, WA, USA
SEC CIK 0001478320

Pipeline (19)

Search pipeline →

  1. ADI-PEG-20, Troriluzole, AZD1390

    Adaptive

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial

  2. Ceftriaxone

    Adaptive

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial

  3. Temozolomide

    Adaptive

    Glioblastoma

    phase 3 small molecule active

    1 trial

  4. Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset

    Adaptive

    Chronic Tonal Tinnitus

    phase 2 other completed

    1 trial

  5. Bacteriophage

    Adaptive

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

  6. Bacteriophage Therapy

    Adaptive

    Osteomyelitis

    phase 2 mab terminated

    1 trial

  7. Bacteriophage Therapy

    Adaptive

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  8. Bendamustine

    Adaptive

    Lymphoma

    phase 2 small molecule active

    1 trial

  9. Intervention A Fluoxetine Hydrochloride (HCl)

    Adaptive

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    2 trials

  10. Intervention B Vilazodone Hydrochloride (HCl)

    Adaptive

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial

  11. Intervention C Daridorexant

    Adaptive

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial

  12. Intervention D SLS-002

    Adaptive

    Post Traumatic Stress Disorder

    phase 2 small molecule on hold

    1 trial

  13. Mosunetuzumab

    Adaptive

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  14. Nivolumab

    Adaptive

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  15. Obinutuzumab

    Adaptive

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial

  16. Phage Therapy

    Adaptive

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  17. Venetoclax monotherapy

    Adaptive

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  18. ANM T30 CR®-System

    Adaptive

    Tinnitus

    approved other completed

    1 trial

  19. Radiation

    Adaptive

    Rectal Cancer

    other completed

    1 trial

Patents (8)

Search patents →

  1. US 12263179

    Lyme disease-associated T cell receptor-related methods

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12264187

    Compositions and methods for targeted therapeutic delivery to bone

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12266425

    T cell receptor sequences diagnostic for COVID-19 and related compositions

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12006517

    Method for purification of bacteriophage particles

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11911345

    Phage dispensing system

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11773138

    Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11390921

    Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11191780

    Extracellular matrix compositions for the treatment of cancer or immunological diseases

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Adaptive?

Adaptive (ADPT) is a biotech company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 19 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Adaptive sponsor?

We track 19 ClinicalTrials.gov-linked programs for Adaptive, including ADI-PEG-20, Troriluzole, AZD1390 and 18 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Adaptive company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.